Dr Hannah Taylor
BSc, MSc, PGCE, PhD
Hannah obtained her BSc in physiology at the University of Liverpool in 2010, and later completed an MSc in biomechanics at the University of Manchester in 2012. After finishing a PGCE, she worked as a secondary science teacher until 2016.
She studied for a PhD in cardiovascular epidemiology at UCL, examining associations between adiposity and cardiac structural and functional outcomes in adolescents, which she completed in 2020. Whilst writing up her thesis, she worked as a post-doc at UCL and looked at health outcomes in secondary school teachers, and the associations between adiposity and psychosocial wellbeing in adolescents.
She began working as a statistical epidemiologist at NDPH in 2020 and spent time investigating associations between adiposity and cardiovascular risk, in both UK-based and international cohorts. In autumn 2022 she began working as a medical statistician in EBCTCG and is currently involved with analysing data from randomised trials of breast cancer treatment.
Hannah is involved with the Early Career Research Networks within NDPH and the British and Irish Hypertension Society (BIHS), and in 2019 she won the Young Investigator Oral Prize at the BIHS Annual Scientific Meeting. She is especially interested in the relationship between body composition and risk for developing non-communicable diseases, including cardiovascular disease and cancer, and the respective roles which age, gender and ethnicity play in modifying these associations.
Body composition and risk factors for cardiovascular disease in global multi-ethnic populations.
Carter JL. et al, (2023), Int J Obes (Lond), 47, 855 - 864
Is Height2.7 Appropriate for Indexation of Left Ventricular Mass in Healthy Adolescents? The Importance of Sex Differences.
Taylor HCM. et al, (2023), Hypertension
Body Composition and Risk of Incident Heart Failure in 1 Million Adults: A Systematic Review and Dose-Response Meta-Analysis of Prospective Cohort Studies.
Oguntade AS. et al, (2023), J Am Heart Assoc, 12
Do tumor infiltrating lymphocytes (TILs) predict benefits from trastuzumab therapy for HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women in 5 trials.
Hills RK. et al, (2023), Journal of Clinical Oncology, 41, 508 - 508
Polygenic risk in Type III hyperlipidaemia and risk of cardiovascular disease: An epidemiological study in UK Biobank and Oxford Biobank.
Pieri K. et al, (2022), Int J Cardiol